Pacific Trade Invest NZ invites you to an important webinar on the FMCG industry in New Zealand. This will be of great ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

New Zealand’s banking landscape faces significant changes as new players target different segments, potentially disrupting ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

GSK launched Shingrix in China in 2020. Meanwhile, the company is also investing in additional manufacturing capacity to meet the expected demand, with a new plant due to come online in 2024.

The company is optimistic about its pipeline, with several new product launches planned for 2025, including treatments in oncology and vaccines. Overall, GSK is poised to continue its focus on ...

On Wednesday, the FDA accepted GSK plc’s (NYSE:GSK) marketing application seeking approval for gepotidacin, an investigational, oral antibiotic for adult and adolescent females with ...

GSK announced positive results from two phase 3 clinical trials evaluating its experimental drug, depemokimab, for chronic rhinosinusitis with nasal polyps affecting 4% of the population.

GSK’s $2.2 billion Zantac settlement today ... largest ever acquisition with a deal to buy Fantech in Australia and New Zealand. Its performance has been boosted by increasing awareness of ...

New Zealand has beaten Sri Lanka by five runs in a sensational finale to their Twenty20 and drawn the series 1-1 in Dambulla.

GSK plc GSK announced new data from the phase III AReSVi-006 (Adult Respiratory Syncytial Virus) study. The study evaluated the efficacy of a single dose of its respiratory syncytial virus (RSV ...